Winning in Corporate Wellness: Trends, ROI & Strategy

Yann Dietrichh
With injunctions becoming a decisive battleground in global SEP and FRAND disputes before the German courts and UPC, this session explores how courts across key jurisdictions are shaping access to—and constraints on—injunctive relief. From the Vodafone/HMD matter in Germany to expanding dockets in Brazil, India, and China, this session unpacks strategic use of injunctions by both SEP holders and implementers, while spotlighting where legal frameworks may shift next. Explore how national courts and the UPC are interpreting proportionality, the influence of the European Commission, and the contrasting positions across global IP enforcement venues.
- Compare how courts in Germany, the UK, the UPC, and the US weigh proportionality, public interest, and enforcement policy when determining injunction relief in SEP cases
- Explore how jurisdictions like Brazil and Colombia are shaping global negotiations through low-cost, fast-granting preliminary injunctions and limited review of FRAND defences
- Discuss the possibilities of injunctive relief in the USA and a change from the eBay standard

Steven Baldwin

Le Chen

Koenraad Wuyds

Tatiana Alvez

Julia Zhu
Supplementary Protection Certificates remain a critical and complex aspect of pharmaceutical patent strategy. This session offers a comprehensive review of recent landmark rulings and evolving practices across Europe, providing life sciences patent holders with key insights to refine their SPC approaches in 2025.
• Explore pivotal cases such as Teva/MSD and Halozyme, and their impact on Articles 3(a), 3(c), and 1(b) concerning combination products and active ingredient interpretation.
• Understand how recent UK decisions, including Merck v Comptroller (2025), reflect divergence from broader European SPC practice, and examine emerging trends in antibody SPCs and unitary SPC legal status.
• Examine the expanded SPC Manufacturing Waiver regime since 2022, including conflicting rulings from Belgium, Germany, and the Netherlands on storage, export, and notification requirements.
• Gain practical guidance on managing waiver-related risks, protecting exclusivity, and navigating cross-jurisdictional challenges in SPC enforcement and litigation.

Karin Pramberger
Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva. She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam.

Sebastian Moore

Karen Guo

Anja Lunze

James Holtom

Ken Aduddell
Ken Aduddell is a thought leader in data infrastructure with over 20 years of experience in the electronics industry. A trusted partner to executives at hyperscalers, his work has focused on the core challenges of data center resilience, including power and coolant systems. An established contributor to the Open Compute Project on the data center resilience chain, Ken offers deep insight into de-risking the inevitable transition to direct liquid cooling and protecting the mission-critical assets that power the AI era. Previously at Rockwell Automation, Ken now leads actnano's initiative to protect critical hardware with this breakthrough coating technology.

Sebastian Moore
